A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors-Reference-Cited by-同舟云学术

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors

Published:2018-03-21 Issue: Volume: Page:e1450710
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Kebenko Maxim¹,Goebeler Marie-Elisabeth²,Wolf Martin³,Hasenburg Annette⁴,Seggewiss-Bernhardt Ruth²,Ritter Barbara³,Rautenberg Beate⁴,Atanackovic Djordje¹,Kratzer Andrea⁵,Rottman James B.⁶^ORCID,Friedrich Matthias⁵,Vieser Eva⁵,Elm Stefanie⁵,Patzak Ingrid⁵^ORCID,Wessiepe Dorothea⁷,Stienen Sabine⁵,Fiedler Walter¹

Affiliation:

1. Department of Oncology/Hematology, Bone Marrow Transplantation and Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

2. Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany

3. Clinic Kassel, Kassel, Germany

4. Department of Gynecology, Johannes Gutenberg University Medical Center, Mainz, Germany

5. Amgen Research (Munich) GmbH, Munich, Germany

6. Amgen Inc., Thousand Oaks, CA, USA

7. Metronomia Clinical Research GmbH, Munich, Germany

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2018.1450710